研究单位：[1]Eli Lilly and Company[2]Kunming Medical College Affiliated First Hospital Kunming,Yunnan,China,650032[3]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650034[4]The Second Affiliated Hospital of Zhejiang University School of Med Hangzhou,Zhejiang,China,310000[5]First Affiliated Hosp of College of Med,Zhejiang University Hangzhou,Zhejiang,China,310003[6]Sir Run Run Shaw Hospital Hangzhou,Zhejiang,China,310016[7]The Second Affiliated Hospital YuYing Childens Hospital of Wenzhou Medical university Wenzhou,Zhejiang,China,325027[8]Tongji Hospital of Tongji University Wuhan,China,430030
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).
